JZP541
/ Jazz
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 06, 2025
BEHAVIORAL AND TRANSCRIPTOMIC EFFECTS OF A NOVEL CANNABINOID ON A RAT VALPROIC ACID MODEL OF AUTISM.
(PubMed, Neuropharmacology)
- "This approach indicated a strong and dose-dependent reduction of the autism-associated gene expression signature in brain samples from animals dosed with JZP541. Our findings demonstrate JZP541 was able to ameliorate ASD associated behavioral deficits, and this was supported by improvements in putative transcriptional biomarkers of ASD."
Journal • Preclinical • Autism Spectrum Disorder • Genetic Disorders
November 08, 2024
A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Jazz Pharmaceuticals | Terminated ➔ Withdrawn
Trial withdrawal • Autism Spectrum Disorder • Genetic Disorders
December 22, 2023
A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=1 | Terminated | Sponsor: Jazz Pharmaceuticals | N=90 ➔ 1 | Trial completion date: Mar 2025 ➔ Nov 2023 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2025 ➔ Nov 2023; A decision has been made to prioritize other pipeline programs and terminate this study.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Autism Spectrum Disorder • Genetic Disorders
November 27, 2023
CALM-IT: Cannabinoid Liquid Medication Intervention Trial
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Sunnybrook Health Sciences Centre | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
August 28, 2023
CALM-IT: Cannabinoid Liquid Medication Intervention Trial
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Sunnybrook Health Sciences Centre
New P2 trial • Alzheimer's Disease • CNS Disorders
August 04, 2023
A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder
(clinicaltrials.gov)
- P2 | N=90 | Recruiting | Sponsor: Jazz Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Autism Spectrum Disorder • Genetic Disorders
1 to 6
Of
6
Go to page
1